Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Moderna (1MRNA) Drug Pipeline

10 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Mrna-1010, Licensed High-Dose Seasonal Influenza VaccineSeasonal InfluenzaPhase IVRecruitingA Study of Updated mRNA Seasonal Influenza VaccinesOct 13, 2026―
Mrna-1010, Fluarix Trivalent, Seasonal Influenza VaccineSeasonal InfluenzaPhase IRecruitingA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenOct 06, 2026
Mrna-1273, Mrna-1283, SpikevaxSars-Cov-2Phase IVRecruitingA Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsOct 02, 2026
Mrna-1273, Mrna-1283Sars-Cov-2Phase IIRecruitingA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeSep 02, 2026
Mrna-1345, Mrna-1365Respiratory Syncytial Virus (Rsv), Human Metapneuomovirus (Hmpv)Phase IRecruitingA Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsAug 10, 2026
Mrna-1469Ebola-Bundibugyo Virus Disease (Ebola-Bdbv)Phase IActive Not RecruitingA Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult ParticipantsJul 27, 2026
Mrna-1982Lyme DiseasePhase IIActive Not RecruitingA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)Apr 24, 2026
Intismeran, Pembrolizumab Coformulated With Berahyaluronidase Alfa, Mrna-4157, V940Non-small Cell Lung CancerPhase IIIRecruitingA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Apr 01, 2026
Mrna-1018-H5InfluenzaPhase IIIActive Not RecruitingA Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsMar 22, 2026
Mrna-1273, Mrna-1283, Mrna-1283.222, Mrna-1273.222, Mrna-1283.815, Mrna-1273.815, Mrna-1283.211, Mrna-1283.529, Mrna-1283.251 Variant-Containing FormulationSars-Cov-2Phase IVRecruitingA Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Nov 25, 2025

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Moderna (IT:1MRNA) have in its pipeline
Moderna IT:1MRNA is currently developing the following drugs: Mrna-1010, Licensed High-Dose Seasonal Influenza Vaccine, Mrna-1010, Fluarix Trivalent, Seasonal Influenza Vaccine, Mrna-1273, Mrna-1283, Spikevax, Mrna-1273, Mrna-1283, Mrna-1345, Mrna-1365, Mrna-1469, Mrna-1982, Intismeran, Pembrolizumab Coformulated With Berahyaluronidase Alfa, Mrna-4157, V940, Mrna-1018-H5, Mrna-1273, Mrna-1283, Mrna-1283.222, Mrna-1273.222, Mrna-1283.815, Mrna-1273.815, Mrna-1283.211, Mrna-1283.529, Mrna-1283.251 Variant-Containing Formulation, Carboplatin, Pembrolizumab, Paclitaxel, Nab-Paclitaxel, Intismeran Autogene, V940, Keytruda, Mrna-4157, Mrna-2808, Mrna-1345, Mrna-4106, Nivolumab/Relatlimab, Influenza Vaccine, Covid-19 Vaccine, Investigational Influenza Vaccine, Mrna-1083 Composition 1 Dose A Lot A, Mrna-1083 Composition 1 Dose A Lot B, Mrna-1083 Composition 1 Dose B, Mrna-1083 Composition 1 Dose C, Mrna-1083 Composition 2 Dose A, Mrna-1083 Composition 2 Dose B, Mrna-1083 Composition 3 Dose A, Mrna-1083 Composition 3 Dose B, Investigational Covid-19 Vaccine Lot A, Investigational Covid-19 Vaccine Lot B, Bcg, Intismeran Autogene, Mrna-4157, Mrna-1195, Fluarix Tetra, Mrna-1273, Mrna-1083, Licensed Influenza Vaccine, Sars-Cov-2 Vaccine, Mrna-0184, Mrna-1273.712, Fluarix, Fluarix Tetra, Influsplit Tetra, Mrna-1010, Alpharix Tetra, Mrna-1403, Carboplatin, Gemcitabine, Cisplatin, Pembrolizumab, Paclitaxel, Pemetrexed, Intismeran Autogene, Keytruda, Mrna-4157, Mrna-1273 Variant-Containing Formulation, Mrna-1083, Investigational Mrna-1273.815, Licensed Spikevax Vaccine, Pembrolizumab, Surgery, Intismeran Autogene, Keytruda, Mrna-4157, V940, Mrna-3210, Mrna-1647, Influenza Vaccine, Covid-19 Vaccine, Mrna-1083, Pembrolizumab, Intismeran Autogene, Keytruda, Mrna-4157, Fluzone Hd, Mrna-1345, Bexsero, Mrna-1608, Mrna-1769, Mrna-1403, Mrna-1405, Mrna-1975, Mrna-1982. These drug candidates are in various stages of clinical development as the company works toward FDA approval.